Company / Cash & Equivalents
Avalo Therapeutics, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$15.9M
FY2025
5-year range
$7.4M / $134.5M
FY2021-FY2025
Trend
-88.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 9 years, ranging from $2M in FY2017 to $135M in FY2024.
Based on SEC 10-K filings.
$16M in FY2025 with a 5-year CAGR of -3.5%.
Improved from $7M to $16M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +6.4%
- 5-Year CAGR
- -3.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.5%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 88.2% year-over-year.
- Peak cash & equivalents was recorded in FY2024.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $15.9M | -88.2% |
| FY2024 | $134.5M | +1714.5% |
| FY2023 | $7.4M | -43.7% |
| FY2022 | $13.2M | -75.9% |
| FY2021 | $54.6M | +188.5% |
| FY2020 | $18.9M | +424.2% |
| FY2019 | $3.6M | -66.1% |
| FY2018 | $10.6M | +330.6% |
| FY2017 | $2.5M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026